Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates


Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant

Read the original post:
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Related Posts